stockrowiRhythm Holdings, Inc.
IRTC Healthcare Medical Devices
iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024.
- Revenue
- +14.9%
- EPS
- −462.5%
- Free cash flow
- −157.6%
- Total debt
- +0.48%
Quarter to September 2026, against a year earlier
Follow IRTC
Alert me
iRhythm Holdings, Inc. (IRTC) EBITDA
iRhythm Holdings, Inc.'s EBITDA for fiscal 2025 was −$31.0M, compared with −$88.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.5M. Over the past ten years it has ranged from −$108.0M (fiscal 2023) to −$14.8M (fiscal 2016); the current reading is higher than 73% of that period. iRhythm Holdings, Inc. ranks 44th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$31.0M | — |
| FY2024 | −$88.3M | — |
| FY2023 | −$108.0M | — |
| FY2022 | −$94.6M | — |
| FY2021 | −$88.5M | — |
| FY2020 | −$36.3M | — |
| FY2019 | −$51.3M | — |
| FY2018 | −$43.2M | — |
| FY2017 | −$25.7M | — |
| FY2016 | −$14.8M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $4.2M | — |
| Mar 2026 | −$9.6M | — |
| Dec 2025 | $6.6M | 3,045.02% |
| Sep 2025 | $211.0K | — |
| 39 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ITGR Integer Holdings Corporation compare | $296.5M |
| HAE Haemonetics Corporation compare | $273.8M |
| LIVN LivaNova PLC compare | $272.6M |
| TMDX TransMedics Group, Inc. compare | $126.9M |
| NEOG Neogen Corporation compare | $116.5M |
| UFPT UFP Technologies, Inc. compare | $116.0M |
| IRTC iRhythm Holdings, Inc. | $1.5M |
| AXGN AxoGen, Inc. compare | −$4.1M |
| TXG 10x Genomics compare | −$40.4M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on IRTC
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement